Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Waters Corporation filings document operating results, proxy governance, capital-structure changes, material agreements, and corporate events for a NYSE-listed life sciences and diagnostics company. Recent 8-K reports include quarterly and annual results, exhibits furnished with earnings releases, and disclosure tied to the completed combination with BD’s Biosciences and Diagnostic Solutions business.
The company’s SEC record also covers senior unsecured notes issued by Augusta SpinCo Corporation and guaranteed by Waters and certain subsidiaries, pro forma and combined financial information for the acquired business, and definitive proxy materials addressing board oversight, shareholder voting matters, executive compensation, and governance practices.
Waters Corporation reported the results of its annual stockholder meeting, where approximately 90,729,508 shares, or about 92.4% of shares entitled to vote, were present or represented by proxy. Stockholders re-elected all nominated directors to the Board, with each candidate receiving a substantial majority of votes cast.
Stockholders also approved the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, they adopted a non-binding, advisory resolution approving the compensation paid to the company’s named executive officers.
Fundsmith LLP files Amendment No. 6 to a Schedule 13G/A reporting ownership of 4,308,930 shares of Waters Corp, representing 4.4%. The filing lists 4,294,850 shares as sole voting power and 4,308,930 as sole dispositive power. The filer certifies that the applicable foreign regulatory scheme is substantially comparable to the U.S. regime and offers to furnish Schedule 13D-equivalent information to Commission staff upon request.
Waters Corporation’s SVP & Chief Financial Officer Amol Chaubal reported a routine tax-related share disposition. On the reported date, 239 shares of common stock were withheld by the company to cover tax obligations tied to vesting of previously granted restricted stock units, rather than sold in the market.
After this withholding, Chaubal directly holds about 7,622.8449 common shares. This total includes 65.4519 shares acquired earlier through the Waters Corporation Amended and Restated 2009 Employee Stock Purchase Plan in a transaction described as exempt under Rule 16b-3(c), indicating ongoing equity participation.
Waters Corporation reports Q1 2026 results that fully reflect its acquisition of BD’s Biosciences & Diagnostic Solutions business. Revenue rose to $1,267 million from $662 million a year earlier, but Waters posted a net loss of $72 million versus prior net income of $121 million, driven by much higher costs and amortization.
The BDS Business Acquisition, structured as a Reverse Morris Trust, carried total consideration of about $12.96 billion, including 38,542 thousand new Waters shares and $4,000 million of assumed debt, and added $7,993 million of goodwill and $8,384 million of identifiable intangibles. Total assets increased to $24,531 million, while total debt rose to $5,215 million, including $3,500 million of new Senior Notes and a $500 million SpinCo Term Loan, materially increasing leverage as Waters integrates its expanded Biosciences and Advanced Diagnostics operations.
Waters Corporation reported strong first quarter 2026 results, with net revenue of $1.267 billion and adjusted diluted EPS of $2.70. This quarter is the first to include the acquired Biosciences and Diagnostic Solutions businesses from Becton, Dickinson and Company.
Organic revenue was $747 million, up 13% as reported and 11% in constant currency versus the first quarter of 2025. Revenue from the acquired Biosciences and Diagnostic Solutions operations contributed $520 million on an owned-period basis.
On a GAAP basis, Waters recorded a diluted loss per share of $0.87, compared to diluted EPS of $2.03 a year earlier, mainly due to acquisition-related purchase accounting charges. Management raised full-year 2026 organic revenue growth and adjusted EPS guidance, reflecting increased momentum across the combined businesses.
Vanguard Capital Management reported beneficial ownership of 7,351,785 shares of Waters Corp common stock, representing 7.49% of the class. The filing states Vanguard has sole power to dispose of 7,351,785 shares and sole voting power over 973,010 shares. The filing is signed by Vanguard's Head of Global Fund Administration and cites affiliated Vanguard entities that exercise voting or dispositive power on various managed accounts.
BlackRock, Inc. filed an Amendment No. 18 to a Schedule 13G/A reporting beneficial ownership of 7,637,586 shares of Waters Corporation Common Stock, representing 7.8% of the class as of 03/31/2026.
The filing lists 6,999,247 shares as sole voting power and 7,637,586 shares as sole dispositive power. The amendment reflects holdings aggregated across certain Reporting Business Units of BlackRock and is signed by a Managing Director on 04/24/2026.
Waters Corporation is soliciting votes for its 2026 annual shareholder meeting and highlighting strong 2025 performance and a transformative acquisition. The company closed the purchase of BD’s Biosciences & Diagnostic Solutions businesses, aiming to build a differentiated global life sciences and diagnostics leader.
For 2025, full-year sales grew 7% on both reported and constant-currency bases, recurring revenue rose 8%, and adjusted earnings per share increased 11% to $13.13. Waters reports a 54% five-year total shareholder return and TSR ahead of major life science tools peers since mid-2020. Executive bonuses under the annual incentive plan paid at 110% of target on corporate results, and 2023 performance stock units paid at 65% of target.
Shareholders are asked to elect 11 directors, ratify PricewaterhouseCoopers as auditor for 2026, and approve on an advisory basis executive compensation. Governance topics include majority voting for directors, proxy access, enhanced stock ownership guidelines (CEO at six times salary, other NEOs at three times), cybersecurity and risk oversight, and an 82% favorable 2025 Say-on-Pay vote.
Waters Corp senior vice president Jianqing Bennett reported a routine tax-related share disposition. On the vesting of previously reported restricted stock units, 302 shares of common stock were withheld by the company at $304.09 per share to cover tax obligations. Following this withholding, Bennett directly holds 6,532 shares of Waters common stock.